aminolevulinic acid

(redirected from Levulan Kerastick)

aminolevulinic acid

 (ALA) [ah-me″no-lev″u-lin´ik]
δ-aminolevulinic acid; a precursor of porphyrins and hemoglobin; serum levels of this acid are elevated in lead poisoning and urinary levels are increased in some porphyrias. The hydrochloride salt is used as a topical photosensitizer in the treatment of nonhyperkeratotic actinic keratoses.

aminolevulinic acid

/ami·no·lev·u·lin·ic ac·id/ (ALA) (-lev″u-lin´ik) δ-aminolevulinic acid; an intermediate in the synthesis of heme; blood and urinary levels are increased in lead poisoning, and urinary levels are increased in some porphyrias. The hydrochloride salt is used as a topical photosensitizer in the treatment of nonhyperkeratotic actinic keratoses.

aminolevulinic acid

a photochemotherapeutic agent.
indication It is used to treat nonhyperkeratotic actinic keratosis of the face and scalp.
contraindication Known hypersensitivity to porphyrins contraindicates this drug's use.
adverse effects Side effects include crusts, hypopigmentation or hyperpigmentation, ulceration, pain, itching, bleeding, and pustules at the site of application.

aminolevulinic acid (ALA)

[am′inōlev′o̅o̅lin′ik]
the aliphatic precursor of heme. It is formed in the body from the condensation of glycine and succinyl coenzyme A and undergoes further condensation to form porphobilinogen. Aminolevulinic acid may be detected in the urine of some patients with porphyria, liver disease, and lead poisoning.

aminolevulinic acid

Oncology A drug used in photodynamic therapy which is absorbed by tumor cells and activated when exposed to light, killing the cells. See Photodynamic therapy.

aminolevulinic acid

see δ-aminolevulinic acid.
References in periodicals archive ?
Integrating Levulan Kerastick and BLU-U Photodynamic Therapy into Your Practice
NASDAQ NMS:DUSA) announces that an update regarding second quarter Levulan Kerastick and BLU-U end user sales will be issued after the close on Thursday July 14, 2005, to be followed by a conference call at 8:45 a.
Levulan Kerastick for topical solution plus DUSA's BLU-U blue light photodynamic therapy illuminator is currently approved for the treatment of minimally to moderately thick actinic keratoses (AKs) of the face or scalp.
Dover of SkinCare Physicians of Chestnut Hill, MA, patients received a series of 3 split-face IPL treatments 3 weeks apart, in which half of the face was pretreated with the Levulan Kerastick followed in 45 plus or minus 15 minutes by IPL treatment, while the other half of the face was treated with the same doses of IPL alone.
DUSA terminated its assignment and agreed to pay an upfront fee and a royalty on sales of the Levulan Kerastick in Canada over a five year term.
Additional patents cover DUSA's Levulan Kerastick formulation of aminolevulinic acid HCl in conjunction with its proprietary blue light technology until June 2019.
DUSA's first products, the Levulan Kerastick 20% Topical Solution with PDT and the BLU-U brand light source were launched in the United States in September 2000 for the treatment of actinic keratoses, or AKs (precancerous skin lesions), of the face or scalp.
R]], aminolevulinic acid, and our proprietary Levulan Kerastick formulation together to treat actinic keratoses.
In combination with Levulan Kerastick, it is indicated for the treatment of Grade 1 and 2 actinic keratoses (AKs) of the face or scalp.
DUSA also markets the BLU-U together with the Levulan Kerastick (aminolevulinic acid HCl) as part of a simple two step photodynamic treatment designed to treat actinic keratosis lesions on the face or scalp.
DUSA is evaluating potential marketing strategies, including marketing the Levulan Kerastick itself.